Everolimus, lanreotide, octreotide and sunitinib for treating advanced neuroendocrine tumours

Agency for Care Effectiveness (ACE)
Record ID 32018002583
Project Status: Completed
Year Published: 2022
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: Singapore
MeSH Terms
  • Carcinoma, Neuroendocrine
  • Neuroendocrine Tumors
  • Antineoplastic Agents
  • Everolimus
  • Octreotide
  • Sunitinib
Organisation Name: Agency for Care Effectiveness (ACE)
Contact Address: Ministry of Health, College of Medicine Building, 16 College Road, Singapore 169854
Contact Name: ACE_HTA@moh.gov.sg
Contact Email: ACE_HTA@moh.gov.sg
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.